Home  |  Investor Relations  |  News  |  Events  |  Clinical Trials  |  Contact Us

Investor Relations
Business Overview & Strategy
Partnerships
Science & Technology
Intellectual Property
Press Releases
Webcasts
Stock Information
SEC Filings
Corporate Governance
Analyst Coverage
Annual Meetings & Materials
Scientific Resources

Investor Relations — NASDAQ: CYTX

Regenerative medicine holds the potential to transform medicine in the same way that computers changed communication

What's New
Jan 30, 2012		Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA
Jan 24, 2012		Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori's APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function
Jan 10, 2012		Biotech Showcase Regenerative Medicine Insight Panel: Cardiovascular, AMI and PAD.
Jan 9, 2012		Biotech Showcase

Shareholder Briefcase | Investor Kit | News and Event Alerts
Download Library | RSS News Feeds

Nov. 2011 Shareholder Letter

Investor Contact:
Tom Baker
Tel: +1.858.875.5258
Email: tbaker@cytori.com

Media Contact:
Megan McCormick
Tel: +1.858.875.5279
Email: mmccormick@cytori.com